Infectious diseases and the immune system are inherently linked, with infections sometimes triggering or worsening autoimmune reactions.
Profiling autoantibodies is crucial for monitoring pathogen exposure, assessing vaccine effects, and understanding the humoral immune response following infection.
Sengenics drives biomarker discovery for infectious diseases with advanced, highly multiplexed protein microarrays. Our technology ensures precise, reproducible detection of disease-relevant autoantibody signatures from patient plasma or serum.
Severe COVID-19 Patients Exhibit Antibodies Targeting a Broader Range of Epitopes
SARS-CoV-2 nucleocapsid antigen epitope coverage in a multi-ethnic cohort (n=138) with varying COVID-19 disease severity. Patients with severe COVID-19 exhibit a significantly broader range of epitopes compared to those with mild COVID-19. Box plots are shown for each disease class, with p-values determined by the Wilcoxon test.
Source: Smith, M., et. al., Age, Disease Severity and Ethnicity Influence Humoral Responses in a Multi-Ethnic COVID-19 Cohort, Viruses (2021).
